Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies

NCT00506857 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00506857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00506857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2003
Completion date
August 31, 2011
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies